Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
OBJECTIVE
We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma.


METHODS
Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review.


RESULTS
A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity.


CONCLUSIONS
The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.
Institut Gustave Roussy, Villejuif, Centre Léon Bérard, Lyon, France.
B
B
Escudier
J P
JP
Droz
F
F
Rolland
M J
MJ
Terrier-Lacombe
G
G
Gravis
P
P
Beuzeboc
B
B
Chauvet
C
C
Chevreau
J C
JC
Eymard
T
T
Lesimple
Y
Y
Merrouche
S
S
Oudard
F
F
Priou
C
C
Guillemare
S
S
Gourgou
S
S
Culine
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D018906:Antineoplastic Agents, Alkylating; D004317:Doxorubicin; D007069:Ifosfamide